Stocks recommended by share market analysts on June 16, 2023: Britannia, Ujjivan Financial Services, Sun Pharma, Trent

Produced by: Harshita
Designed by: Mohsin Shaikh

Stock brokerages such as Emkay Global, HDFC Securities, Motilal Oswal, and Nuvama Institutional Equities have come out with research reports on select stocks namely Britannia, Ujjivan Financial Services, Sun Pharma, Trent. Here's what brokerages said about these counters

Stocks to buy

Emkay Global has a ‘Buy’ rating on Britannia shares with a target price of Rs 5,700. According to the brokerage, Britannia Industries is well-placed in the core biscuits segment and is promptly addressing adjacency gaps to evolve into a ‘Total Foods Company’

Britannia share price target

Analysts at Emkay Global believe that with a solid brand price straddle in place, Britannia has been widening product availability with improved distribution, and has bolstered sourcing with an amplified capex cycle. “We see the shift from opex to capex aiding earnings. Muted rural demand, inflation and competition are key risks to our call,” they said

Britannia widening
product availability

HDFC Securities has a ‘buy’ rating on Ujjivan Financial Services stock with a target price of Rs 491. “Looking at the growth opportunities we feel that the stock is trading at attractive valuations and UFSL the holding company, which is trading at discount based on the swap ratio, looks like a candidate for re-rating," the brokerage said

Ujjivan Financial Services
share price target

According to analysts at HDFC Securities, investors can buy the shares of UFSL between Rs 395-403 and add more on dips at Rs 340-345 band. “We expect the base case fair value of Rs 442 and the bull case fair value of Rs 491 over the next 3-4 quarters,” they said

Buy UFSL at Rs 395;
add more on dips

Motilal Oswal has a ‘buy’ rating on Sun Pharma shares with a target price of Rs 1,160. Based on the substantial changes witnessed over the past two decades, the brokerage continues to maintain a positive outlook for the company

Sun Pharma share
price target

According to analysts at Motilal Oswal expect 13% earnings CAGR over FY23-25. “The margin expansion is expected to be gradual as we expect increased R&D expenditure on multiple projects in the specialty segment,” they said

Double-digit earnings
growth for Sun Pharma

Nuvama Institutional Equities has a ‘Buy’ call on Trent stock with a target price of Rs 1,908 per share. With Zudio picking up pace, and the opportunity size in value retail being much larger, the brokerage believes this new format would drive Trent’s next leg of growth over the coming decade

Trent share price target

Analysts at Nuvama believe that valuations imply a premium, but Trent’s success, execution with Westside’s scale-up underpin their belief that it can replicate the same at Zudio. Sub-optimal economics for Zudio’s new stores; e-commerce; and increase in subsidiaries losses remain the key risks

Tailwinds for Trent

Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Business Today. Investors should consult their financial advisors before taking any position

Disclaimer